Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.00 (0.12%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Onxeo – executive interview

Onxeo – executive interview

Onxeo — 2 videos in collection

More on this equity

Onxeo has a proprietary platON platform based on a unique decoy technology in the field of DNA damage repair inhibition. The lead asset, AsiDNA, is in a Phase Ib triple combination trial with chemotherapy in solid tumours and a second Phase Ib/II trial that aims to demonstrate AsiDNA’s potential to abrogate tumour resistance to PARP inhibitors. The second compound, OX401, is in late preclinical development, optimised to target PARP and is capable of activating the STING pathway. In this video, the CEO of Onxeo Judith Greciet provides an update on the company’s activities and upcoming newsflow.

< Previous
Next >

You may also be interested in these:

Healthcare

Onxeo – Edison Open House interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free